Cargando…

Lep gene and leptin concentration in serum of schizophrenia patients with metabolic syndrome

INTRODUCTION: Schizophrenia is associated with lower life expectancy due to cardiovascular disease. Metabolic syndrome (MetS) occupies an important place among the main problems. Indicators of hormones regulating metabolism may be appealing candidates as biomarkers of metabolic side-effects. Certain...

Descripción completa

Detalles Bibliográficos
Autores principales: Boiko, A., Pozhidaev, I., Paderina, D., Kornetova, E., Ivanova, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471844/
http://dx.doi.org/10.1192/j.eurpsy.2021.438
_version_ 1784789171828686848
author Boiko, A.
Pozhidaev, I.
Paderina, D.
Kornetova, E.
Ivanova, S.
author_facet Boiko, A.
Pozhidaev, I.
Paderina, D.
Kornetova, E.
Ivanova, S.
author_sort Boiko, A.
collection PubMed
description INTRODUCTION: Schizophrenia is associated with lower life expectancy due to cardiovascular disease. Metabolic syndrome (MetS) occupies an important place among the main problems. Indicators of hormones regulating metabolism may be appealing candidates as biomarkers of metabolic side-effects. Certain role belongs to genetic factors that might be the basis of sensitivity to development of MetS. OBJECTIVES: The aim is to study polymorphisms of leptin gene (LEP) and serum leptin concentration in schizophrenia patients with metabolic syndrome. METHODS: After obtaining informed consent, patients with schizophrenia (ICD-10: F20) were included: 91 patients for biochemical research and 463 patients for genotyping. Patients were divided into two groups: 46 (119) with MetS; 45 (344) without it. Concentration of leptin was measured on an analyzer MAGPIX (Luminex, USA). Determination of 4 polymorphisms (rs2167270, rs3828942, rs10954173, rs4731426) of LEP was performed by PCR. Differences were considered significant at p<0.05. RESULTS: The leptin concentration is significantly (p<0.001) higher in MetS (13511.5 [7392.5; 28278.75] pg/ml) compared to patients without MetS (6662 [2131.5; 11380] pg/ml). Significant differences were found in the distribution of rs3828942 (GG:GA:AA): 25.9%:44%:30.2% in MetS and 31.2%:52.6%:16.2% without MetS (χ(2)=10.545, p=0.005). The genotype AA and the allele A have a predisposing effect on the development of MetS (OR(1)=2.247, C.I:1.248-4.046; OR(2)=1.475, C.I:1.093-1.991, χ(2)=6.49, p=0.01). CONCLUSIONS: A number of features are observed in patients with MetS, which impair the functioning of patients. These investigations should aim to optimize the approach to assess the risk of MetS. The study was supported by grants from the RSF 19-75-10012 (genetic research) and 18-15-00011 (determination of leptin concentration) DISCLOSURE: The study was supported by grants from the Russian Science Foundation №19-75-10012 (genetic research) and №18-15-00011 (determination of leptin concentration)
format Online
Article
Text
id pubmed-9471844
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-94718442022-09-29 Lep gene and leptin concentration in serum of schizophrenia patients with metabolic syndrome Boiko, A. Pozhidaev, I. Paderina, D. Kornetova, E. Ivanova, S. Eur Psychiatry Abstract INTRODUCTION: Schizophrenia is associated with lower life expectancy due to cardiovascular disease. Metabolic syndrome (MetS) occupies an important place among the main problems. Indicators of hormones regulating metabolism may be appealing candidates as biomarkers of metabolic side-effects. Certain role belongs to genetic factors that might be the basis of sensitivity to development of MetS. OBJECTIVES: The aim is to study polymorphisms of leptin gene (LEP) and serum leptin concentration in schizophrenia patients with metabolic syndrome. METHODS: After obtaining informed consent, patients with schizophrenia (ICD-10: F20) were included: 91 patients for biochemical research and 463 patients for genotyping. Patients were divided into two groups: 46 (119) with MetS; 45 (344) without it. Concentration of leptin was measured on an analyzer MAGPIX (Luminex, USA). Determination of 4 polymorphisms (rs2167270, rs3828942, rs10954173, rs4731426) of LEP was performed by PCR. Differences were considered significant at p<0.05. RESULTS: The leptin concentration is significantly (p<0.001) higher in MetS (13511.5 [7392.5; 28278.75] pg/ml) compared to patients without MetS (6662 [2131.5; 11380] pg/ml). Significant differences were found in the distribution of rs3828942 (GG:GA:AA): 25.9%:44%:30.2% in MetS and 31.2%:52.6%:16.2% without MetS (χ(2)=10.545, p=0.005). The genotype AA and the allele A have a predisposing effect on the development of MetS (OR(1)=2.247, C.I:1.248-4.046; OR(2)=1.475, C.I:1.093-1.991, χ(2)=6.49, p=0.01). CONCLUSIONS: A number of features are observed in patients with MetS, which impair the functioning of patients. These investigations should aim to optimize the approach to assess the risk of MetS. The study was supported by grants from the RSF 19-75-10012 (genetic research) and 18-15-00011 (determination of leptin concentration) DISCLOSURE: The study was supported by grants from the Russian Science Foundation №19-75-10012 (genetic research) and №18-15-00011 (determination of leptin concentration) Cambridge University Press 2021-08-13 /pmc/articles/PMC9471844/ http://dx.doi.org/10.1192/j.eurpsy.2021.438 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Boiko, A.
Pozhidaev, I.
Paderina, D.
Kornetova, E.
Ivanova, S.
Lep gene and leptin concentration in serum of schizophrenia patients with metabolic syndrome
title Lep gene and leptin concentration in serum of schizophrenia patients with metabolic syndrome
title_full Lep gene and leptin concentration in serum of schizophrenia patients with metabolic syndrome
title_fullStr Lep gene and leptin concentration in serum of schizophrenia patients with metabolic syndrome
title_full_unstemmed Lep gene and leptin concentration in serum of schizophrenia patients with metabolic syndrome
title_short Lep gene and leptin concentration in serum of schizophrenia patients with metabolic syndrome
title_sort lep gene and leptin concentration in serum of schizophrenia patients with metabolic syndrome
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471844/
http://dx.doi.org/10.1192/j.eurpsy.2021.438
work_keys_str_mv AT boikoa lepgeneandleptinconcentrationinserumofschizophreniapatientswithmetabolicsyndrome
AT pozhidaevi lepgeneandleptinconcentrationinserumofschizophreniapatientswithmetabolicsyndrome
AT paderinad lepgeneandleptinconcentrationinserumofschizophreniapatientswithmetabolicsyndrome
AT kornetovae lepgeneandleptinconcentrationinserumofschizophreniapatientswithmetabolicsyndrome
AT ivanovas lepgeneandleptinconcentrationinserumofschizophreniapatientswithmetabolicsyndrome